{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:35:07Z","timestamp":1785443707701,"version":"3.56.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.medine.2025.502254","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:53:17Z","timestamp":1757677997000},"page":"502254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytokine release syndrome and hemophagocytic syndrome associated with immunotherapy: A narrative review"],"prefix":"10.1016","volume":"50","author":[{"given":"Eric","family":"Mayor-V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cuenca Fito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Marcos-Neira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1ndido","family":"D\u00edaz-Lagares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Gomila-Sintes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Albal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Garc\u00eda-Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2025.502254_bib0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"10.1016\/j.medine.2025.502254_bib0010","unstructured":"Tipos de tratamiento. Washington DC: National Institute of Cancer; 2024 [accessed 15 Jan 2025]. Available from: https:\/\/www.cancer.gov\/espanol\/cancer\/tratamiento\/tipos."},{"key":"10.1016\/j.medine.2025.502254_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care."},{"key":"10.1016\/j.medine.2025.502254_bib0020","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.medine.2025.502254_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medine.2025.502254_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.medine.2025.502254_bib0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0040","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.medine.2025.502254_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0050","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medine.2025.502254_bib0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0060","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0070","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medine.2025.502254_bib0075","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00134-017-4943-5","article-title":"Understanding cytokine release syndrome","volume":"44","author":"G\u00f6del","year":"2018","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0192623317752101","article-title":"T-cell immunotherapies and the role of nonclinical assessment: the balance between efficacy and pathology","volume":"46","author":"Sharpe","year":"2018","journal-title":"Toxicol Pathol."},{"key":"10.1016\/j.medine.2025.502254_bib0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.medine.2025.502254_bib0090","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.medine.2025.502254_bib0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medine.2025.502254_bib0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med."},{"key":"10.1016\/j.medine.2025.502254_bib0105","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medine.2025.502254_bib0110","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy."},{"key":"10.1016\/j.medine.2025.502254_bib0115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","article-title":"Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation","volume":"25","author":"Raj","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medine.2025.502254_bib0125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10120-017-0774-x","article-title":"High adherence to the Western, Prudent, and Mediterranean dietary patterns and risk of gastric adenocarcinoma: MCC-Spain study","volume":"21","author":"Castell\u00f3","year":"2018","journal-title":"Gastric Cancer."},{"key":"10.1016\/j.medine.2025.502254_bib0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.medin.2019.01.009","article-title":"Cytokine release syndrome. Reviewing a new entity in the intensive care unit","volume":"43","author":"Garc\u00eda Roche","year":"2019","journal-title":"Med Intensiva (Engl Ed)."},{"key":"10.1016\/j.medine.2025.502254_bib0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.medine.2025.502254_bib0140","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00134-020-06193-1","article-title":"Acute life-threatening toxicity from CAR T-cell therapy","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0145","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0150","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00134-020-06002-9","article-title":"Ten things the hematologist wants you to know about CAR-T cells","volume":"46","author":"B\u00f6ll","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0155","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.medine.2025.502254_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medine.2025.502254_bib0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0175","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.20.01616","article-title":"How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T-Cell therapies","volume":"39","author":"Reagan","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0180","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3343\/alm.2023.0388","article-title":"Current challenges in chimeric antigen receptor T-cell therapy in patients with B-cell lymphoid malignancies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med."},{"key":"10.1016\/j.medine.2025.502254_bib0185","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0190","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.medine.2025.502254_bib0195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.medine.2025.502254_bib0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0205","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med."},{"key":"10.1016\/j.medine.2025.502254_bib0210","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0220","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0225","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medine.2025.502254_bib0230","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/CJI.0000000000000243","article-title":"Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy","volume":"41","author":"Liu","year":"2018","journal-title":"J Immunother."},{"key":"10.1016\/j.medine.2025.502254_bib0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcrc.2020.02.010","article-title":"Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome","volume":"57","author":"Stahl","year":"2020","journal-title":"J Crit Care."},{"key":"10.1016\/j.medine.2025.502254_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111761","article-title":"Multi-centers experience using therapeutic plasma exchange for corticosteroid\/tocilizumab-refractory cytokine release syndrome following CAR-T therapy","volume":"130","author":"Pu","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.medine.2025.502254_bib0245","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0250","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.medine.2025.502254_bib0255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5492\/wjccm.v7.i6.73","article-title":"Intensive care unit complications and outcomes of adult patients with hemophagocytic lymphohistiocytosis: a retrospective study of 16 cases","volume":"7","author":"Kapoor","year":"2018","journal-title":"World J Crit Care Med."},{"key":"10.1016\/j.medine.2025.502254_bib0260","article-title":"High mortality of HLH in ICU regardless etiology or treatment","volume":"8","author":"Bichon","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.medine.2025.502254_bib0265","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1751143719893865","article-title":"Haemophagocytic lymphohistiocytosis in adult critical care","volume":"21","author":"Bauchmuller","year":"2020","journal-title":"J Intensive Care Soc."},{"key":"10.1016\/j.medine.2025.502254_bib0270","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer."},{"key":"10.1016\/j.medine.2025.502254_bib0275","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medine.2025.502254_bib0280","unstructured":"HScore for reactive hemophagocytic syndrome. [accessed 15 Jan 2026] Available from: https:\/\/www.mdcalc.com\/calc\/10089\/hscore-reactive-hemophagocytic-syndrome#why-use."},{"key":"10.1016\/j.medine.2025.502254_bib0285","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. [accessed 15 Jan 2026] Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.medine.2025.502254_bib0290","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0295","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medine.2025.502254_bib0300","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jtct.2023.06.004","article-title":"Thinking clearly with anakinra","volume":"29","author":"Frey","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.medine.2025.502254_bib0305","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0310","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica."},{"key":"10.1016\/j.medine.2025.502254_bib0315","article-title":"Goodbye etoposide? Taking the leap to ruxolitinib in haemophagocytic lymphohistiocytosis","author":"Merrill","year":"2024","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medine.2025.502254_bib0320","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4329\/wjr.v16.i10.579","article-title":"Successful management of infection and macrophage activation syndrome patients using low-dose etoposide: a case report","volume":"16","author":"Gao","year":"2024","journal-title":"World J Radiol."},{"key":"10.1016\/j.medine.2025.502254_bib0325","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1358\/dot.2020.56.7.3145359","article-title":"Emapalumab for the treatment of hemophagocytic lymphohistiocytosis","volume":"56","author":"Cheloff","year":"2020","journal-title":"Drugs Today (Barc)."},{"key":"10.1016\/j.medine.2025.502254_bib0330","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medine.2025.502254_bib0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medine.2025.502254_bib0340","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica."},{"key":"10.1016\/j.medine.2025.502254_bib0345","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medine.2025.502254_bib0350","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.medine.2025.502254_bib0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.medine.2025.502254_bib0360","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children","volume":"4","author":"Diorio","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.medine.2025.502254_bib0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-024-00495-6","article-title":"Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies","volume":"13","author":"Wang","year":"2024","journal-title":"Exp Hematol Oncol."},{"key":"10.1016\/j.medine.2025.502254_bib0370","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere."},{"key":"10.1016\/j.medine.2025.502254_bib0375","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit Care."}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572725001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572725001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:23:09Z","timestamp":1768314189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572725001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2173572725001444"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2025.502254","relation":{},"ISSN":["2173-5727"],"issn-type":[{"value":"2173-5727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine release syndrome and hemophagocytic syndrome associated with immunotherapy: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2025.502254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2025.502254","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. and SEMICYUC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502254"}}